دورية أكاديمية
Development of a quantitative COVID-19 multiplex assay and its use for serological surveillance in a low SARS-CoV-2 incidence community.
| العنوان: | Development of a quantitative COVID-19 multiplex assay and its use for serological surveillance in a low SARS-CoV-2 incidence community. |
|---|---|
| المؤلفون: | Guarino C; Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States of America., Larson E; Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States of America., Babasyan S; Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States of America., Rollins A; Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States of America., Joshi LR; Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States of America., Laverack M; Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States of America., Parrilla L; Cayuga Medical Center, Ithaca, NY, United States of America., Plocharczyk E; Cayuga Medical Center, Ithaca, NY, United States of America., Diel DG; Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States of America., Wagner B; Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States of America. |
| المصدر: | PloS one [PLoS One] 2022 Jan 21; Vol. 17 (1), pp. e0262868. Date of Electronic Publication: 2022 Jan 21 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: San Francisco, CA : Public Library of Science |
| مواضيع طبية MeSH: | Antibodies, Viral/*chemistry , COVID-19/*diagnosis , COVID-19 Serological Testing/*methods , Coronavirus Nucleocapsid Proteins/*immunology , SARS-CoV-2/*immunology , Spike Glycoprotein, Coronavirus/*immunology, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Neutralizing/chemistry ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; COVID-19/blood ; COVID-19/epidemiology ; COVID-19 Serological Testing/standards ; Coronavirus Nucleocapsid Proteins/chemistry ; Epidemiological Monitoring ; Female ; Humans ; Immunoglobulin A/chemistry ; Immunoglobulin A/immunology ; Immunoglobulin G/chemistry ; Immunoglobulin G/immunology ; Immunoglobulin M/chemistry ; Immunoglobulin M/immunology ; Male ; Middle Aged ; New York/epidemiology ; Phosphoproteins/chemistry ; Phosphoproteins/immunology ; Protein Interaction Domains and Motifs ; Recombinant Proteins/chemistry ; Recombinant Proteins/immunology ; SARS-CoV-2/classification ; Sensitivity and Specificity ; Spike Glycoprotein, Coronavirus/chemistry |
| مستخلص: | A serological COVID-19 Multiplex Assay was developed and validated using serum samples from convalescent patients and those collected prior to the 2020 pandemic. After initial testing of multiple potential antigens, the SARS-CoV-2 nucleocapsid protein (NP) and receptor-binding domain (RBD) of the spike protein were selected for the human COVID-19 Multiplex Assay. A comparison of synthesized and mammalian expressed RBD proteins revealed clear advantages of mammalian expression. Antibodies directed against NP strongly correlated with SARS-CoV-2 virus neutralization assay titers (rsp = 0.726), while anti-RBD correlation was moderate (rsp = 0.436). Pan-Ig, IgG, IgA, and IgM against NP and RBD antigens were evaluated on the validation sample sets. Detection of NP and RBD specific IgG and IgA had outstanding performance (AUC > 0.90) for distinguishing patients from controls, but the dynamic range of the IgG assay was substantially greater. The COVID-19 Multiplex Assay was utilized to identify seroprevalence to SARS-CoV-2 in people living in a low-incidence community in Ithaca, NY. Samples were taken from a cohort of healthy volunteers (n = 332) in early June 2020. Only two volunteers had a positive result on a COVID-19 PCR test performed prior to serum sampling. Serological testing revealed an exposure rate of at least 1.2% (NP) or as high as 5.7% (RBD), higher than the measured incidence rate of 0.16% in the county at that time. This highly sensitive and quantitative assay can be used for monitoring community exposure rates and duration of immune response following both infection and vaccination. Competing Interests: I have read the journal’s plicy and the authors of this manuscript have the following competing interests: BW holds a patent entitled ‘Enhancing serological assays via fusion proteins’ US10101327B2 describing the fusion protein based technology described in the COVID-19 Multiplex Assay. This does not alter our adherence to PLOS ONE policies on sharing data and materials. |
| References: | Clin Chim Acta. 2020 Oct;509:18-21. (PMID: 32485155) Nat Microbiol. 2020 Dec;5(12):1598-1607. (PMID: 33106674) Science. 2020 Nov 27;370(6520):. (PMID: 32994364) mBio. 2020 Oct 13;11(5):. (PMID: 33051368) Euro Surveill. 2020 Jul;25(28):. (PMID: 32700672) Emerg Microbes Infect. 2020 Dec;9(1):1497-1505. (PMID: 32529906) Emerg Infect Dis. 2020 Jul;26(7):1478-1488. (PMID: 32267220) Front Pediatr. 2020 Sep 11;8:547. (PMID: 33042908) Clin Chem. 2020 Aug 1;66(8):1055-1062. (PMID: 32402061) Clin Infect Dis. 2020 Nov 19;71(16):2027-2034. (PMID: 32221519) J Virol. 2019 Oct 29;93(22):. (PMID: 31462575) Int J Infect Dis. 2020 May;94:49-52. (PMID: 32251798) Virology. 2019 May;531:219-232. (PMID: 30928700) Transl Res. 2021 Jun;232:60-74. (PMID: 33582244) J Clin Virol. 2020 Aug;129:104511. (PMID: 32593133) Rev Esp Quimioter. 2020 Aug;33(4):258-266. (PMID: 32492991) Nat Commun. 2020 Oct 8;11(1):5064. (PMID: 33033249) Clin Chem Lab Med. 2020 Jun 25;58(7):1156-1159. (PMID: 32301750) Nat Med. 2020 Aug;26(8):1200-1204. (PMID: 32555424) Clin Chim Acta. 2020 Aug;507:164-166. (PMID: 32343948) Clin Microbiol Infect. 2020 Oct;26(10):1386-1394. (PMID: 32603801) medRxiv. 2020 Jul 21;:. (PMID: 32743610) J Clin Virol. 2020 Aug;129:104468. (PMID: 32485620) J Virol. 2021 Mar 10;95(11):. (PMID: 33692203) J Infect Dis. 2020 Oct 1;222(9):1452-1461. (PMID: 32766833) Lancet. 2020 Aug 1;396(10247):313-319. (PMID: 32534626) Nat Med. 2020 Aug;26(8):1193-1195. (PMID: 32504052) Eur J Clin Microbiol Infect Dis. 2020 Dec;39(12):2271-2277. (PMID: 32681308) J Clin Microbiol. 2020 Jul 23;58(8):. (PMID: 32381641) Clin Infect Dis. 2021 Jul 15;73(2):e458-e465. (PMID: 32649743) PLoS One. 2018 Nov 15;13(11):e0206679. (PMID: 30440016) Clin Microbiol Infect. 2021 Feb;27(2):253-257. (PMID: 33035672) Clin Infect Dis. 2020 Jul 28;71(15):778-785. (PMID: 32198501) Nat Commun. 2020 Sep 17;11(1):4698. (PMID: 32943630) Clin Infect Dis. 2021 Jan 27;72(2):249-253. (PMID: 33501969) J Clin Virol. 2020 Aug;129:104539. (PMID: 32679298) Ann Epidemiol. 2020 Aug;48:23-29.e4. (PMID: 32648546) J Infect Dis. 2020 Nov 13;222(12):1955-1959. (PMID: 32906151) Sci Rep. 2021 Mar 23;11(1):6614. (PMID: 33758278) mBio. 2020 Oct 16;11(5):. (PMID: 33067385) Biosens Bioelectron. 2020 Dec 1;169:112643. (PMID: 33007615) J Appl Lab Med. 2020 Sep 1;5(5):908-920. (PMID: 32428207) J Clin Microbiol. 2020 Nov 18;58(12):. (PMID: 32917729) J Clin Virol. 2020 Jul;128:104394. (PMID: 32416599) medRxiv. 2020 Jun 18;:. (PMID: 32588002) Vet Immunol Immunopathol. 2012 Apr 15;146(2):125-34. (PMID: 22405681) J Clin Virol. 2020 Aug;129:104512. (PMID: 32563180) J Clin Microbiol. 2021 Jan 21;59(2):. (PMID: 33127841) J Clin Microbiol. 2020 Dec 17;59(1):. (PMID: 33067270) J Clin Virol. 2020 Aug;129:104480. (PMID: 32505777) Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100747. (PMID: 33898863) Ann Intern Med. 2020 Jun 2;172(11):726-734. (PMID: 32282894) J Clin Virol. 2020 Jul;128:104413. (PMID: 32403010) Clin Chem Lab Med. 2020 Jul 28;58(8):1357-1364. (PMID: 32447328) J Allergy Clin Immunol. 2020 Jul;146(1):23-34. (PMID: 32445839) J Clin Microbiol. 2020 Aug 24;58(9):. (PMID: 32580948) Am J Clin Pathol. 2020 Aug 5;154(3):293-304. (PMID: 32583852) Clin Chem. 2020 Aug 1;66(8):1104-1106. (PMID: 32484887) Clin Chim Acta. 2020 Oct;509:1-7. (PMID: 32485157) Clin Chim Acta. 2020 Oct;509:79-82. (PMID: 32526218) J Infect Dis. 2021 Feb 3;223(2):197-205. (PMID: 33535236) J Clin Microbiol. 2021 Jan 21;59(2):. (PMID: 33139422) mBio. 2020 Sep 29;11(5):. (PMID: 32994333) Vet Immunol Immunopathol. 2011 Apr 15;140(3-4):190-8. (PMID: 21208663) Vet Immunol Immunopathol. 2009 Feb 15;127(3-4):242-8. (PMID: 19027964) J Pediatr. 2020 Dec;227:45-52.e5. (PMID: 32827525) Indian J Med Res. 2020 Jul & Aug;152(1 & 2):48-60. (PMID: 32952144) |
| المشرفين على المادة: | 0 (Antibodies, Neutralizing) 0 (Antibodies, Viral) 0 (Coronavirus Nucleocapsid Proteins) 0 (Immunoglobulin A) 0 (Immunoglobulin G) 0 (Immunoglobulin M) 0 (Phosphoproteins) 0 (Recombinant Proteins) 0 (Spike Glycoprotein, Coronavirus) 0 (nucleocapsid phosphoprotein, SARS-CoV-2) 0 (spike protein, SARS-CoV-2) |
| تواريخ الأحداث: | Date Created: 20220121 Date Completed: 20220201 Latest Revision: 20231103 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC8782306 |
| DOI: | 10.1371/journal.pone.0262868 |
| PMID: | 35061843 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!